Ending Deficits and Turning Around... U.S. Pharmaceutical Stocks Gain 80 Billion Won Today

Amneal Pharmaceuticals (NASDAQ: AMRX), a U.S.‐based generic drugmaker, closed at $12.26 on the Nasdaq on the 25th, up 1.57%. Its market capitalization stands at about $3.86 billion (roughly ₩5 trillion), with a single‐day increase of approximately $61.5 million (around ₩80 billion).

In its full‐year 2025 results announced on February 27, Amneal reported revenue of $3.02 billion (about ₩4 trillion), an 8% year-over-year increase, and swung from a net loss of $117 million to a net profit of $72 million (approximately ₩100 billion). Strong sales of its specialty drugs—Parkinson’s treatment CREXONT and thyroid disorder therapy UNITHROID—alongside expansion in biosimilars, underpinned this growth. The company is also broadening its pipeline into GLP-1 class weight-loss therapies and a denosumab biosimilar for osteoporosis.

Headquartered in Bridgewater, New Jersey, Amneal is a full-line pharmaceutical company producing and marketing finished dosage generics and biosimilars, primarily in North America and India. Co-CEOs and brothers Chirag Patel and Chintu Patel are leveraging the pricing competitiveness built in generics to drive expansion into biosimilars and the obesity and diabetes treatment markets.